CBS 2019
CBSMD教育中心
English

动脉粥样硬化性心血管疾病预防

科研文章

荐读文献

Coronary calcium as a predictor of coronary events in four racial or ethnic groups Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER Trial Adenosine and adenosine receptor-mediated action in coronary microcirculation Long-Term All-Cause and Cause-Specific Mortality in Asymptomatic Patients With CAC ≥1,000: Results From the CAC Consortium Myocardial bridging of the left anterior descending coronary artery is associated with reduced myocardial perfusion reserve: a 13N-ammonia PET study 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older Adults The Year in Cardiovascular Medicine 2020: Coronary Prevention: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of coronary prevention is Professor Ramon Estruch, Dr Luis Ruilope, and Professor Francesco Cosentino. Mark Nicholls meets them Clinical Risk Factors and Atherosclerotic Plaque Extent to Define Risk for Major Events in Patients Without Obstructive Coronary Artery Disease: The Long-Term Coronary Computed Tomography Angiography CONFIRM Registry Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes

Guideline2018 Sep 25;138(13):e415-e418.

JOURNAL:Circulation. Article Link

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

Al-Khatib SM, Stevenson WG, Ackerman MJ et al. Keywords: AHA Scientific Statements; CT imaging; ECG; MR imaging; acute coronary syndrome; ambulatory ECG monitoring; antiarrhythmic drug therapy; arrhythmogenic cardiomyopathy; athletes; cardiac electrophysiology; cardiac resynchronization therapy; cardiomyopathy; catheter ablation; congenital heart disease; echocardiography; electrophysiological testing; genetic arrhythmias; guidelines; heart failure; imaging; implantable and external cardioverter devices; implantable cardioverter-defibrillator; medication-induced arrhythmias; myocardial infarction; premature ventricular beats; resuscitation; sarcoidosis; specific pathology (eg, congenital heart disease, myocarditis, renal failure); stable coronary artery disease; sudden cardiac arrest; sudden cardiac death; torsades de pointes; ventricular fibrillation; ventricular tachycardia

FULL TEXT PDF